Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 12.45% ...

Qure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to ...

Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

Good morning! Here are the five things you need to know in local business news to start your busy Wednesday, and Great Scott's development, the World Cup's impact, new JetBlue flights and the great ...

Verition Fund Management LLC lowered its position in uniQure (NASDAQ:QURE – Free Report) by 77.9% during the third quarter, ...

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

Fintel reports that on December 10, 2024, Raymond James upgraded their outlook for uniQure N.V. (NasdaqGS:QURE) from ...

Qure (NASDAQ:QURE – Get Free Report) was upgraded by research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Wednesday. Other research analysts have also ...

The U.S. FDA has greenlit the first steps of Uniqure NV’s accelerated approval pathway for gene therapy AMT-130 to treat Huntington’s disease. The agency said data from the ongoing phase I/II studies ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of ...